Adimarket Named as Distributor for Innovative GCell Micrograft Technology
The partnership between Adimarket and Global Medical Group delivers an FDA-compliant stem cells procedure to physicians practicing regenerative medicine across the globe
MIAMI LAKES, Florida—Adimarket, LLC, a subsidiary of the Global Stem Cells Group (GSCG), has entered an agreement with Global Medical Group (GMG) to distribute the brand’s newest product featuring GCell technology. It will be available for purchase to regenerative medicine practitioners via Adimarket’s online store.
Global Medical Group recently announced the launch of their GCell micrograft technology, an autologous tissue suspension that boasts minimal manipulation. The product has application implications for a wide range of medical uses, including orthopedics, dermatology, cosmetic gynecology, aesthetics, and hair loss.
GCell technology would allow regenerative medicine practitioners to continue practicing their adult stem cells-based procedures, as the product meets FDA compliance standards. GMG’s innovative product uses micrograft technology and is a closed system medical device that harnesses the natural and powerful restorative capabilities of adipose tissue. Because the procedure can be performed without using enzymes, GCell technology maintains FDA compliance.
The GCell SVF (Stromal Vascular Fraction) procedure can be performed in-office in around 30 minutes, while previous procedures could take up to two hours. It also utilizes only local anesthesia, and performing physicians only have to collect 15 ml of fat instead of the 50 ml required for traditional protocols.
GCell technology may hold exciting applications for clients looking for treatment options for wound care, hair loss, orthopedic conditions, or aesthetic concerns.
“We are pleased to partner with the Global Medical Group to offer their cutting edge GCell technology in Adimarket’s product portfolio,” said Benito Novas, CEO of the Global Stem Cells Group. “There is a possibility that this innovative technology could lead to incredible advances in various treatment protocols, including those related to wound care, hair loss, orthopedic injuries, or aesthetics. And because it is FDA compliant, GCell technology will be a highly attractive option to regenerative medicine practitioners in the US and abroad.”
The first unit will be launched in the US market next month. Physicians looking to incorporate GCell technology into their practices will be able to find it at www.adimarket.net.
